EGFR + MET Bispecific Antibody
Amivantamab simultaneously binds EGFR and MET, two pathways involved in tumor growth and resistance.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Intravenous Amivantamab, Subcutaneous Amivantamab + Hyaluronidase), By Application (First-Line EGFR Exon 19 Deletion / L858R NSCLC, First-Line EGFR Exon 20 Insertion NSCLC, Post-EGFR TKI Common-Mutation NSCLC, Post-Platinum Exon 20 Insertion NSCLC, Other Investigational Solid Tumors), By Treatment Regimen (Amivantamab + Lazertinib, Amivantamab + Chemotherapy, Amivantamab Monotherapy), By End User (Comprehensive Cancer Centers, Hospitals, Community Oncology Clinics), By Distribution Channel (Hospital / Specialty Pharmacy, Direct Oncology Supply, Specialty Distribution Networks), and Regional Forecast, 2026-2034
The global amivantamab market was valued at USD 0.73 billion in 2025 and is estimated at USD 1.10 billion in 2026. The market is projected to reach USD 2.80 billion by 2034, representing a 12.4% CAGR during 2026–2034.
Amivantamab is an EGFR- and MET-directed bispecific antibody commercialized as RYBREVANT for EGFR-mutated non-small cell lung cancer. The franchise now includes intravenous amivantamab and subcutaneous amivantamab with hyaluronidase, with approved use across multiple EGFR-mutated NSCLC settings and combination regimens.
Commercial momentum accelerated sharply in 2025 and 2026. Johnson & Johnson reported USD 734 million in worldwide 2025 RYBREVANT / LAZCLUZE franchise sales and USD 546 million in the first half of 2026, up 70.4% from the comparable prior-year period. The launch of subcutaneous RYBREVANT FASPRO and simplified monthly dosing is expected to improve treatment convenience and increase clinic capacity.
The market is also expanding through broader biomarker-defined use. FDA companion-diagnostic listings support EGFR exon 20 insertion patient selection, while 2026 clinical updates continued to reinforce first-line amivantamab-based regimens in common EGFR mutations and exon 20 insertion disease. Johnson & Johnson also received Priority Review for subcutaneous amivantamab in recurrent or metastatic head and neck squamous cell carcinoma, creating an important potential indication expansion.
Source: FDA subcutaneous amivantamab approval; Johnson & Johnson monthly dosing approval; Johnson & Johnson Q2 2026 sales; FDA companion diagnostics; Johnson & Johnson HNSCC Priority Review.
The study defines the global amivantamab market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Intravenous Amivantamab; Subcutaneous Amivantamab + Hyaluronidase |
| By Application | First-Line EGFR Exon 19 Deletion / L858R NSCLC; First-Line EGFR Exon 20 Insertion NSCLC; Post-EGFR TKI Common-Mutation NSCLC; Post-Platinum Exon 20 Insertion NSCLC; Other Investigational Solid Tumors |
| By Treatment Regimen | Amivantamab + Lazertinib; Amivantamab + Chemotherapy; Amivantamab Monotherapy |
| By End User | Comprehensive Cancer Centers; Hospitals; Community Oncology Clinics |
| By Distribution Channel | Hospital / Specialty Pharmacy; Direct Oncology Supply; Specialty Distribution Networks |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; China; Japan; South Korea; Australia and other approved markets |
| Key Market Player | Johnson & Johnson / Janssen Biotech |
The market includes commercial amivantamab products and amivantamab-containing branded regimens used in approved EGFR-mutated cancer indications, including intravenous RYBREVANT and subcutaneous RYBREVANT FASPRO.
Research-grade antibodies, unrelated EGFR or MET antibodies, companion diagnostic revenue and LAZCLUZE revenue sold independently from the amivantamab franchise are outside the core market boundary.
Amivantamab-based combinations now reach substantially broader patient groups than the original post-platinum exon 20 insertion indication.
RYBREVANT FASPRO reduces administration from hours to minutes and can simplify chair utilization, nursing time and patient scheduling.
Johnson & Johnson reported USD 546 million in worldwide RYBREVANT / LAZCLUZE sales during the first half of 2026, representing strong year-over-year growth.
FDA companion diagnostic authorizations support identification of eligible EGFR mutation subgroups and make molecular testing a prerequisite for treatment.
Amivantamab regimens require management of dermatologic reactions, administration-related reactions and other treatment-specific adverse events, increasing the importance of experienced oncology teams.
Source: J&J Q2 2026; FDA SC approval; FDA CDx; J&J WCLC.
The 2025 U.S. approval and 2026 monthly dosing schedule create a simpler administration pathway than conventional intravenous infusion.
FDA-approved monthly administration in combination with lazertinib reduces treatment visits while maintaining the established regimen framework.
First-line use in common EGFR mutations and exon 20 insertion disease materially expands lifetime patient exposure.
FDA authorization of a liquid-biopsy companion diagnostic in 2026 expands plasma-based identification of exon 20 insertion candidates.
Priority Review in recurrent or metastatic head and neck squamous cell carcinoma could create the first major commercial expansion beyond lung cancer.
Source: J&J monthly dosing; FDA CDx; J&J HNSCC; J&J WCLC.
Amivantamab combines dual receptor targeting with immune-effector engagement, while formulation innovation is reducing administration burden.
Amivantamab simultaneously binds EGFR and MET, two pathways involved in tumor growth and resistance.
The original commercial formulation is given by intravenous infusion and remains widely used across established indications.
Amivantamab is combined with hyaluronidase for rapid subcutaneous administration across approved IV indications.
Tumor or plasma testing identifies EGFR mutation subgroups eligible for specific amivantamab regimens.
Source: FDA SC approval; FDA CDx; J&J WCLC.
By type, the market is segmented into intravenous amivantamab and subcutaneous amivantamab with hyaluronidase. Intravenous therapy remains the largest installed segment, while subcutaneous therapy is the fastest-growing format.
RYBREVANT IV has the longest clinical and commercial history and remains embedded across multiple approved NSCLC regimens.
RYBREVANT FASPRO reduces administration time from hours to minutes and supports simplified every-two-week, every-three-week or monthly schedules depending on regimen and market.
Intravenous amivantamab will remain important through the forecast period, but subcutaneous use should capture a rising share because of treatment convenience and clinic-capacity benefits.
By application, the market is segmented across first-line common EGFR-mutated NSCLC, first-line exon 20 insertion NSCLC, post-EGFR TKI common-mutation NSCLC, post-platinum exon 20 insertion NSCLC and investigational solid tumors.
Amivantamab plus lazertinib expands use into the broad common-EGFR first-line population.
Amivantamab plus chemotherapy addresses a historically difficult-to-treat mutation subgroup.
Amivantamab-containing regimens are used after progression on EGFR-targeted therapy in selected patients.
This was the original commercial use and remains an important monotherapy setting.
Head and neck cancer and other EGFR/MET-driven tumors represent future expansion opportunities.
First-line common EGFR-mutated NSCLC should become the largest value application as commercial uptake broadens beyond the original exon 20 insertion niche.
By treatment regimen, the market is segmented into amivantamab plus lazertinib, amivantamab plus chemotherapy and amivantamab monotherapy. Combination regimens now drive the largest growth.
The chemotherapy-free first-line regimen targets common EGFR mutations and supports the broadest current franchise expansion.
Combination with carboplatin and pemetrexed expands use in first-line EGFR exon 20 insertion NSCLC.
Monotherapy remains used in post-platinum exon 20 insertion disease and provides the historical commercial foundation.
Combination regimens will account for an increasing share of revenue, while monotherapy remains clinically relevant in narrower approved settings.
By end user, the market is segmented into comprehensive cancer centers, hospitals and community oncology clinics. Comprehensive cancer centers lead early adoption of biomarker-driven and newly approved regimens.
Major oncology centers have broad molecular testing, multidisciplinary expertise and rapid adoption of new targeted regimens.
Hospital oncology departments provide infusion or subcutaneous treatment and manage treatment-related adverse events.
Simplified subcutaneous dosing can make amivantamab easier to deliver outside large academic centers.
Comprehensive centers will continue to shape early uptake, while subcutaneous administration should accelerate migration into community oncology.
By distribution channel, the market is segmented into hospital or specialty pharmacy, direct oncology supply and specialty distribution networks. Specialty oncology distribution leads because cold-chain handling and reimbursement support are essential.
Specialty pharmacy pathways support reimbursement, handling and scheduled administration of high-cost biologic therapy.
Integrated health systems can purchase and manage amivantamab through centralized oncology procurement.
Specialty distributors extend product reach to community practices while maintaining biologic handling standards.
Specialty pharmacy and specialty distribution will remain the dominant channels, with direct procurement concentrated in large health systems.
Regional demand follows regulatory approvals, EGFR testing and reimbursement. North America is the largest market, while Asia-Pacific has strong long-term potential because EGFR mutations are more common in Asian NSCLC populations.
The United States has multiple approved amivantamab regimens, current subcutaneous approval and broad molecular testing.
European approvals include subcutaneous amivantamab and multiple NSCLC regimens, supporting strong specialist adoption.
Japan, China and South Korea have large EGFR-mutated NSCLC populations and expanding access to precision oncology.
Adoption depends on molecular-testing access and reimbursement for premium targeted biologics.
Use is concentrated in advanced tertiary oncology centers and privately funded precision-oncology programs.
Source: J&J WCLC; FDA SC approval.
Amivantamab commercialization is tightly linked to biomarker-defined indications, companion diagnostics and formulation-specific approvals.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Subcutaneous U.S. approval | FDA approved amivantamab and hyaluronidase-lpuj on December 17, 2025 across all indications approved for the IV formulation. | Created a new administration format. |
| Monthly dosing approval | FDA approved a simplified monthly schedule in February 2026 for first-line use with lazertinib. | Reduces treatment-visit frequency. |
| Liquid companion diagnostic | FDA authorized Guardant360 Liquid CDx in May 2026 for RYBREVANT exon 20 insertion patient selection. | Expands plasma-based testing. |
| Potential new indication | FDA granted Priority Review in July 2026 for subcutaneous amivantamab in recurrent or metastatic head and neck cancer. | Creates a potential non-NSCLC market. |
Source: FDA SC approval; J&J monthly; FDA CDx; J&J HNSCC.
The amivantamab market itself is concentrated because Johnson & Johnson is the commercial owner. Competitive pressure comes from other EGFR-targeted therapies and regimen choices rather than direct branded amivantamab competitors.
RYBREVANT and RYBREVANT FASPRO form the sole commercial amivantamab franchise.
EGFR TKIs compete for first-line and post-progression positioning based on mutation, prior therapy and regimen strategy.
Chemotherapy remains part of several treatment pathways and is combined with amivantamab in exon 20 insertion disease.
Source: FDA SC approval; J&J WCLC; J&J Q2 2026.
September 2026: Johnson & Johnson presented new WCLC data including final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC.
July 2026: FDA granted Priority Review to subcutaneous amivantamab for recurrent or metastatic head and neck squamous cell carcinoma.
February 2026: FDA approved a simplified monthly RYBREVANT FASPRO dosing schedule with lazertinib for first-line common EGFR-mutated NSCLC.
December 2025: FDA approved RYBREVANT FASPRO across all indications approved for IV amivantamab.
Source: J&J WCLC; J&J HNSCC; J&J monthly; FDA SC.
The global amivantamab market market is projected to grow from USD 1.10 billion in 2026 to USD 2.80 billion by 2034, at a 12.4% CAGR during 2026–2034. Growth is expected to be supported by first-line use, broader subcutaneous adoption and possible expansion beyond NSCLC. The strongest near-term drivers are common-EGFR first-line treatment, simplified monthly dosing and increasing community-oncology feasibility.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| First-line expansion | Broader EGFR-mutated populations now receive amivantamab-based therapy. | Expands volume. |
| Subcutaneous conversion | Minutes-long administration improves clinic capacity. | Supports uptake. |
| Monthly dosing | Fewer visits improve convenience. | Strengthens persistence. |
| Companion diagnostics | Liquid biopsy broadens patient identification. | Improves access. |
| New tumor types | Head and neck cancer is under regulatory review. | Creates upside. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global amivantamab market landscape.
24LifeScience develops amivantamab market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines Johnson & Johnson reported franchise sales, current FDA approvals and companion-diagnostic records, and current clinical-development updates. The 2026 estimate reflects current commercial scale, while the displayed 2034 endpoint is consistent with a 12.4% CAGR.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 0.73 billion in 2025 and is estimated at USD 1.10 billion in 2026. It is projected to reach USD 2.80 billion by 2034 at a 12.4% CAGR during 2026–2034.
Amivantamab is a bispecific antibody that targets both EGFR and MET and is commercialized as RYBREVANT.
Subcutaneous amivantamab with hyaluronidase is the fastest-growing format because it reduces administration time from hours to minutes.
First-line treatment of common EGFR-mutated NSCLC is the largest growth opportunity because it expands use beyond the original exon 20 insertion population.
North America is the largest regional market, led by the United States.
Johnson & Johnson reported USD 734 million in worldwide 2025 RYBREVANT / LAZCLUZE franchise sales.
FDA approved monthly subcutaneous dosing, authorized a liquid companion diagnostic for exon 20 insertion disease, and granted Priority Review for a head and neck cancer indication.
Johnson & Johnson / Janssen Biotech is the commercial manufacturer and owner of the RYBREVANT franchise.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.